15 July 2020 

An interim analysis of a Phase I clinical trial assessing Moderna‘s Covid-19 vaccine candidate, mRNA-1273, has found the product to be generally safe and well-tolerated without any serious adverse events reported through to day 57. Adverse events were said to be generally transient and mild to moderate in severity.

A study by professor Yaakov Nahmias at Hebrew University in Israel has showed that an existing cholesterol medicine, called fenofibrate, could ‘downgrade’ Covid-19 threat level to that of a common cold. The findings are based on lab tests conducted on human lung cells infected with SARS-CoV-2.

AstraZeneca has partnered with IQVIA to speed-up clinical trials of its Covid-19 vaccine candidate, AZD1222. This collaboration, which is part of the US Government’s Operation Warp Speed, is intended to accelerate trials of the vaccine in the US by leveraging IQVIA’s Virtual Trial solutions.

Dosing has commenced in a Phase I clinical trial of Medicago’s plant-derived Covid-19 vaccine candidate. The trial will evaluate the safety, tolerability, and immunogenicity of the vaccine candidate at three dose levels, unadjuvanted or adjuvanted with either Dynavax‘s CpG 1018 adjuvant or GSK‘s adjuvant technology.